Home > Insider Trading > Filing (0000950170-24-088020)

Filing Details

Accession Number:: 0000950170-24-088020
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-07-30 17:16:35
Reporting Period:: 2024-07-26

Accepted Time:: 2024-07-30 17:16:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1253689	Glycomimetics Inc	GLYC	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053890	Raymond Debbane	750 Lexington Avenue 30Th Floor New York NY 10022	No	No	No	No
1340096	Invus Public Equities Advisors, Llc	750 Lexington Avenue 30Th Floor New York NY 10022	No	No	No	No
1340097	Invus Public Equities, L.p.	750 Lexington Avenue 30Th Floor New York NY 10022	No	No	No	No
2005245	Siren, L.l.c.	C/O The Invus Group, Llc 750 Lexington Avenue 30Th Floor New York NY 10022	No	No	No	No
2005369	Invus Global Management, Llc	750 Lexington Avenue 30Th Floor New York NY 10022	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-07-26	258,335	$0.24	8,330,729	No	4	S	Direct
Common Stock	Disposition	2024-07-29	363,949	$0.24	7,966,780	No	4	S	Direct
Common Stock	Disposition	2024-07-30	756,835	$0.22	7,209,945	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.
Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.2451 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.23 to $0.241 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.24 pershare, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.